These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26757472)

  • 1. Tinzaparin vs Warfarin for Acute Venous Thromboembolism--Reply.
    Khorana AA; Lee AY;
    JAMA; 2016 Jan; 315(2):200-1. PubMed ID: 26757472
    [No Abstract]   [Full Text] [Related]  

  • 2. Tinzaparin vs Warfarin for Acute Venous Thromboembolism.
    Maruyama A; Tejani AM; Perry TL
    JAMA; 2016 Jan; 315(2):200. PubMed ID: 26757471
    [No Abstract]   [Full Text] [Related]  

  • 3. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer.
    Di Nisio M; Rutjes AW
    Evid Based Med; 2016 Apr; 21(2):66. PubMed ID: 26786824
    [No Abstract]   [Full Text] [Related]  

  • 5. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
    Hyers TM; Spyropoulos AC;
    J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update in the treatment of venous thromboembolism.
    Garcia DA; Spyropoulos AC
    Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of venous thromboembolism with tinzaparin in oncological patients.
    Ageno W; Barni S; Di Nisio M; Falanga A; Imberti D; Labianca RF; Mantovani L
    Minerva Med; 2019 Jun; 110(3):251-258. PubMed ID: 30990000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation quality and the risk of recurrence of venous thromboembolism.
    Poli D; Antonucci E; Ciuti G; Abbate R; Prisco D
    Thromb Haemost; 2007 Nov; 98(5):1148-50. PubMed ID: 18000626
    [No Abstract]   [Full Text] [Related]  

  • 10. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term treatment of venous thromboembolism in patients with cancer].
    Šmrha J; Kessler P; Poul H; Harudová M
    Vnitr Lek; 2016; 62(6):449-52. PubMed ID: 27485842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of the management of venous thromboembolism in Japan].
    Nakamura M
    Nihon Rinsho; 2014 Jul; 72(7):1298-302. PubMed ID: 25163325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulation in Patients with Liver Cirrhosis].
    Cheong JY
    Korean J Gastroenterol; 2017 Nov; 70(5):218-222. PubMed ID: 29161790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
    [No Abstract]   [Full Text] [Related]  

  • 16. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
    Rhodes S; Bond S
    Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing paradigms in the management of venous thromboembolism.
    Weitz JI
    Am Heart Hosp J; 2006; 4(2):135-41. PubMed ID: 16687960
    [No Abstract]   [Full Text] [Related]  

  • 18. Periprocedural anticoagulation management of patients with venous thromboembolism.
    McBane RD; Wysokinski WE; Daniels PR; Litin SC; Slusser J; Hodge DO; Dowling NF; Heit JA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):442-8. PubMed ID: 20139361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
    O'Connell CL; Liebman HA
    Expert Rev Hematol; 2008 Dec; 1(2):175-82. PubMed ID: 21082922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does antithrombotic therapy improve survival in cancer patients?
    Cunningham MS; Preston RJ; O'Donnell JS
    Blood Rev; 2009 May; 23(3):129-35. PubMed ID: 19046797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.